117 related articles for article (PubMed ID: 36418272)
1. [Cardiovascular events and risk factors in hematological neoplasms patients treated with anthracyclines].
Dai MY; Zhang YL; Sun YX; Lyu X; Zhang XX; Sun XL; Fang FQ; Liu JW; Xia YL; Liu Y
Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Nov; 50(11):1058-1063. PubMed ID: 36418272
[No Abstract] [Full Text] [Related]
2. Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010.
Larsen CM; Garcia Arango M; Dasari H; Arciniegas Calle M; Adjei E; Rico Mesa J; Scott CG; Thompson CA; Cerhan JR; Haddad TC; Goetz MP; Herrmann J; Villarraga HR
JAMA Netw Open; 2023 Feb; 6(2):e2254669. PubMed ID: 36735254
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insights.
Shibata T; Nohara S; Morikawa N; Shibao K; Ito S; Shibata R; Toh U; Nagafuji K; Fukami K; Fukumoto Y
Eur J Prev Cardiol; 2023 Dec; 30(18):1941-1949. PubMed ID: 37352112
[TBL] [Abstract][Full Text] [Related]
4. Myocardial Strain Is Associated with Adverse Clinical Cardiac Events in Patients Treated with Anthracyclines.
Ali MT; Yucel E; Bouras S; Wang L; Fei HW; Halpern EF; Scherrer-Crosbie M
J Am Soc Echocardiogr; 2016 Jun; 29(6):522-527.e3. PubMed ID: 27068546
[TBL] [Abstract][Full Text] [Related]
5. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events.
Vanwagner LB; Bhave M; Te HS; Feinglass J; Alvarez L; Rinella ME
Hepatology; 2012 Nov; 56(5):1741-50. PubMed ID: 22611040
[TBL] [Abstract][Full Text] [Related]
6. Predictive Factors of Therapy-Related Cardiovascular Events in Patients with Lymphoma Receiving Anthracyclines.
Lopez-Garcia A; Macia E; Gomez-Talavera S; Castillo E; Morillo D; Tuñon J; Ibañez B; Cordoba R
Med Sci (Basel); 2024 Apr; 12(2):. PubMed ID: 38804379
[TBL] [Abstract][Full Text] [Related]
7. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines.
Mousavi N; Tan TC; Ali M; Halpern EF; Wang L; Scherrer-Crosbie M
Eur Heart J Cardiovasc Imaging; 2015 Sep; 16(9):977-84. PubMed ID: 25925220
[TBL] [Abstract][Full Text] [Related]
8. [Predictive value of N-terminal B-type natriuretic peptide on outcome of elderly hospitalized non-heart failure patients].
Li YY; Liang YD; Yao SM; Zheng PP; Zeng XZ; Cui LL; Guo D; Wang H; Yang JF
Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Aug; 48(8):661-668. PubMed ID: 32847322
[No Abstract] [Full Text] [Related]
9. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk.
van Nimwegen FA; Schaapveld M; Janus CP; Krol AD; Petersen EJ; Raemaekers JM; Kok WE; Aleman BM; van Leeuwen FE
JAMA Intern Med; 2015 Jun; 175(6):1007-17. PubMed ID: 25915855
[TBL] [Abstract][Full Text] [Related]
10. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H
Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483
[No Abstract] [Full Text] [Related]
11. Heart failure with preserved ejection fraction: comparison of patients with and without angina pectoris (from the Duke Databank for Cardiovascular Disease).
Mentz RJ; Broderick S; Shaw LK; Fiuzat M; O'Connor CM
J Am Coll Cardiol; 2014 Jan; 63(3):251-8. PubMed ID: 24161322
[TBL] [Abstract][Full Text] [Related]
12. Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines.
Gongora CA; Drobni ZD; Quinaglia Araujo Costa Silva T; Zafar A; Gong J; Zlotoff DA; Gilman HK; Hartmann SE; Sama S; Nikolaidou S; Suero-Abreu GA; Jacobsen E; Abramson JS; Hochberg E; Barnes J; Armand P; Thavendiranathan P; Nohria A; Neilan TG
JACC Heart Fail; 2022 Aug; 10(8):559-567. PubMed ID: 35902159
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of fragmented QRS on a 12-lead ECG in patients with acute myocardial infarction.
Lorgis L; Jourda F; Hachet O; Zeller M; Gudjoncik A; Dentan G; Stamboul K; Guenancia C; Mock L; Cottin Y;
Heart Lung; 2013; 42(5):326-31. PubMed ID: 23850293
[TBL] [Abstract][Full Text] [Related]
14. Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines.
Baech J; Hansen SM; Lund PE; Soegaard P; Brown PN; Haaber J; Jørgensen J; Starklint J; Josefsson P; Poulsen CB; Juul MB; Torp-Pedersen C; El-Galaly TC
Br J Haematol; 2018 Dec; 183(5):717-726. PubMed ID: 30406945
[TBL] [Abstract][Full Text] [Related]
15. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
16. Ischemic risk in patients with heart failure with preserved ejection fraction: A post hoc analysis of the TOPCAT data.
He X; Dong B; Liang W; Wu Y; Chen Y; Dong Y; He J; Liu C
Atherosclerosis; 2022 Mar; 344():1-6. PubMed ID: 35101783
[TBL] [Abstract][Full Text] [Related]
17. Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.
van der Voort A; van Ramshorst MS; van Werkhoven ED; Mandjes IA; Kemper I; Vulink AJ; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS
JAMA Oncol; 2021 Jul; 7(7):978-984. PubMed ID: 34014249
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials.
Maraldo MV; Giusti F; Vogelius IR; Lundemann M; van der Kaaij MA; Ramadan S; Meulemans B; Henry-Amar M; Aleman BM; Raemaekers J; Meijnders P; Moser EC; Kluin-Nelemans HC; Feugier P; Casasnovas O; Fortpied C; Specht L;
Lancet Haematol; 2015 Nov; 2(11):e492-502. PubMed ID: 26686259
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of the incidence of syncope and the influencing factors of death in patients with cardiovascular critical emergency].
Bai X; Wang X; Zhang Y; Liu D; Jing Z; Fan M; Fan Y; Fan P
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Mar; 33(3):324-328. PubMed ID: 33834974
[TBL] [Abstract][Full Text] [Related]
20. Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.
Figtree GA; Vernon ST; Hadziosmanovic N; Sundström J; Alfredsson J; Arnott C; Delatour V; Leósdóttir M; Hagström E
Lancet; 2021 Mar; 397(10279):1085-1094. PubMed ID: 33711294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
